Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases

Phase 1

Completed

Conditions: Central Nervous System (CNS) Metastases
Metastatic Breast Cancer

Interventions: Drug: Lapatinib in Tandem With Capecitabine

First Posted Date: 2016-01-08

Last Posted Date: 2021-01-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 11

Registration Number: NCT02650752

Locations: 🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States

and more 6 locations

Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

Phase 1

Active, not recruiting

Conditions: Neuroblastoma
High-Risk

Interventions: Drug: cyclophosphamide
Biological: NK cells
Biological: hu3F8
Drug: rIL-2

First Posted Date: 2016-01-08

Last Posted Date: 2025-02-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 85

Registration Number: NCT02650648

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older

Phase 1

Withdrawn

Conditions: Acute Lymphoblastic Leukemia (ALL)
Newly Diagnosed Philadelphia Chromosome Negative
Aged 60 Years or Older

Interventions: Drug: Erwinia Chrysanthemi asparaginase

First Posted Date: 2016-01-06

Last Posted Date: 2017-06-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT02647190

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Dose Escalation Trial of Stereotactic Body Radiotherapy (SBRT) After Induction Chemotherapy for Locally Advanced Pancreatic Cancer

Phase 1

Completed

Conditions: Pancreatic Cancer

Interventions: Radiation: Stereotactic Body Radiotherapy (SBRT)

First Posted Date: 2015-12-31

Last Posted Date: 2024-12-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 11

Registration Number: NCT02643498

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (Consent and follow-up only), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Consent and follow-up only), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (Consent and follow-up only), Montvale, New Jersey, United States

and more 4 locations

Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients

Phase 1

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Enzalutamide
Drug: Enzalutamide with Sorafenib

First Posted Date: 2015-12-30

Last Posted Date: 2021-03-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 28

Registration Number: NCT02642913

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 2 locations

Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma

Phase 1

Withdrawn

Conditions: Malignant Pleural Mesothelioma

Interventions: Drug: Pemetrexed/Cisplatin
Radiation: Pleural Intensity Modulated Radiation Therapy
Device: MRI

First Posted Date: 2015-12-24

Last Posted Date: 2016-12-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT02639767

Locations: 🇺🇸
Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 3 locations

Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Mantle Cell Lymphoma
Untreated

Interventions: Drug: Lenalidomide
Drug: R-CHOP
Drug: high-dose cytarabine (HIDAC)

First Posted Date: 2015-12-17

Last Posted Date: 2023-11-08

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 49

Registration Number: NCT02633137

Locations: 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 4 locations

DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas

Active, not recruiting

Conditions: B-cell Non-Hodgkin Lymphoma
Aggressive

Interventions: Other: collected at pre-treatment tumor biopsy
Other: Peripheral blood tests
Device: PET/CT

First Posted Date: 2015-12-17

Last Posted Date: 2024-11-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 501

Registration Number: NCT02633111

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Memorial Sloan Kettering Nassau, Uniondale, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 8 locations

Cardiopulmonary Fitness in Long-Term Survivors of HPV-related Oropharynx Cancers

Withdrawn

Conditions: Oropharynx Cancers

Interventions: Other: blood draw
Behavioral: study questionnaire
Other: cardiopulmonary exercise testing (CPET)
Other: DXA (dual-energy x-ray absorptiometry) scan

First Posted Date: 2015-12-11

Last Posted Date: 2018-01-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT02628912

Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors

Completed

Conditions: HER2-Positive Breast Cancer Survivors
Trastuzumab Cardiotoxicity

Interventions: Device: 2D Echocardiogram
Device: Cardiopulmonary exercise testing and post-CPET cardiac function

First Posted Date: 2015-11-25

Last Posted Date: 2024-04-11

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 58

Registration Number: NCT02615054

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy